Superdrol (Methasteron / Methyldrostanolone) is a synthetic anabolic reference compound derived from Dihydrotestosterone (DHT). Structurally, it is 2α,17α-dimethyl-5α-androst-3-one-17β-ol — a c-17α alkylated derivative of Drostanolone (Masteron) that allows for oral bioavailability in pharmacological and analytical studies.

Key Research Features

• Compound: Methyldrostanolone (Superdrol)
• Class: Oral anabolic-androgenic reference compound
• Structure: 17α-alkylated DHT analogue (no ester chain)
• Half-life: Approximately 8–9 hours (short-acting oral form)

Research Overview

Superdrol has been used in pre-clinical anabolic and androgenic activity models to evaluate skeletal muscle growth, strength metrics, and hepatic metabolism under 17α-alkylated conditions. The compound exhibits strong anabolic potential and minimal aromatization, providing a clear framework for studying non-estrogenic anabolic pathways and hepatotoxicity thresholds in oral steroid research.

Product Specifications

• Form: Oral reference tablets
• Strength: 10 mg Methyldrostanolone per tablet
• Quantity: 56 tablets per pack

Reference Sampling Protocol (Educational)

Reference Notes & Handling

• Cycle length: 4–6 weeks recommended for controlled study observation.
• Half-life consideration: Due to its short half-life, split dosage every 8–9 hours for stable plasma reference levels.
• Supportive supplementation: Use of liver-support references (e.g., silymarin or milk thistle) recommended to mitigate hepatic strain in extended exposure studies.
• Do not exceed: 40 mg total daily reference amount or 6-week observation duration.

Observed Outcomes (Research Literature)

• Significant increases in lean mass and strength metrics across short-term observation cycles.
• Non-aromatizing compound—no conversion to estrogen in in-vitro assays.
• Hepatotoxicity markers elevated in high-dose or extended-duration models due to 17α-methylation.
• Enhanced muscle hardness and density with limited water retention in tissue studies.

Findings derived from animal and in-vitro models; not indicative of human clinical outcomes.

Research Considerations

• Stacking compatibility: Evaluated in models with non-methylated injectables (e.g., nandrolone, trenbolone analogues) for comparative response curves.
• Avoid concurrent use with other 17α-alkylated compounds to reduce hepatic stress in research animals.
• Monitoring: Regular analysis of ALT, AST, and bilirubin values in extended studies recommended.

Potential Side Observations

• Elevated liver enzyme markers (ALT, AST) in prolonged cycles.
• Mild androgenic effects: oily skin, acne, increased hair growth.
• No direct estrogenic conversion observed in vitro.

What’s in the Box

• 56 × 10 mg Superdrol (Methyldrostanolone) tablets

Why Choose EU Pharmaceuticals?

EU Pharmaceuticals reference compounds are manufactured under analytical testing standards (HPLC, MS) to ensure identity, purity, and consistent concentration. Designed for educational, chemical, and research environments requiring reproducible data on anabolic-androgenic reference agents.

For laboratory, educational, and research use only. Not for human or veterinary ingestion or therapeutic application. No medical or performance claims are made or implied. Buyer assumes responsibility for lawful handling and regulatory compliance.